Biophytis S.A. Logo

Biophytis S.A.

Clinical-stage biotech developing drugs for age-related neuromuscular and retinal diseases.

ALBPS | PA

Overview

Corporate Details

ISIN(s):
FR0012816825 (+4 more)
LEI:
9695008GIE061NBGU106
Country:
France
Address:
14 AVENUE DE L'OPERA, 75001 PARIS
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow the degenerative processes associated with aging and improve functional outcomes for patients. The company's scientific approach targets and activates key biological resilience pathways to counteract the effects of stresses leading to age-related diseases. Its lead drug candidate, BIO101 (20-hydroxyecdysone), is an orally administered small molecule in late-stage clinical development for neuromuscular conditions, including sarcopenia (Phase 3) and muscle wasting associated with obesity (Phase 2). The company's pipeline also includes Macuneos (BIO201), a small molecule being developed for retinal diseases such as dry age-related macular degeneration (AMD) and Stargardt disease.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Biophytis S.A. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-04 07:00
Regulatory News Service
Biophytis announces its participation in the BIO International Convention from …
English 155.1 KB
2025-06-04 07:00
Regulatory News Service
Biophytis annonce sa participation à la BIO International Convention du 16 au 1…
French 161.2 KB
2025-05-30 22:00
Report Publication Announcement
Information on the Annual Financial Statements
English 103.8 KB
2025-05-30 22:00
Report Publication Announcement
Information sur les comptes annuels
French 172.5 KB
2025-05-15 07:00
Environmental & Social Information
Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 20…
English 144.3 KB
2025-05-15 07:00
Regulatory News Service
Biophytis met en lumière son approche innovante du traitement de l’obésité lors…
French 129.9 KB
2025-04-22 07:00
Regulatory News Service
Biophytis cible la restauration de la mobilité chez les patients obèses
French 143.1 KB
2025-04-22 07:00
Earnings Release
Biophytis targets mobility restoration in patients with obesity
English 140.1 KB
2025-04-09 07:00
Regulatory News Service
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
English 175.0 KB
2025-04-09 07:00
Regulatory News Service
Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obési…
French 169.7 KB
2025-03-28 22:00
Share Issue/Capital Change
Biophytis announces the settlement and delivery of its €2.6 million private pla…
English 534.3 KB
2025-03-28 22:00
Share Issue/Capital Change
Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions…
French 340.2 KB
2025-03-26 07:35
Share Issue/Capital Change
Biophytis announces the successful completion of a €2,6 million private placeme…
English 381.7 KB
2025-03-26 07:35
Share Issue/Capital Change
Biophytis annonce le succès d'un placement privé d'environ 2,6 millions d'euros
French 381.0 KB
2025-03-24 07:30
Regulatory News Service
Biophytis announces new non-clinical data further supporting its mission to pio…
English 242.6 KB

Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Biophytis S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-11-22 N/A Other Buy 8,443,190 79,365.99 EUR
2020-12-16 N/A Other Sell 500,000 499,000.00 EUR
2020-12-16 N/A Other Other 313,417 N/A
2020-04-30 N/A Other Other 2,955,701 177,342.06 EUR

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM
Adtraction Group AB Logo
A partner marketing platform driving online sales for brands with a performance-based model.
Sweden ADTR
Adventure, Inc. Logo
A Japanese OTA providing competitive rates for global travel bookings in over 30 languages.
Japan 6030
Adverty AB Logo
Adtech platform for seamless, non-intrusive brand advertising in games, AR, and VR.
Sweden ADVT
Adways Inc. Logo
Global mobile marketing firm providing ad tech and agency services, focused on Asian markets.
Japan 2489
Aidma Marketing Communication Corporation Logo
Data-driven sales promotions for the retail industry, offering both digital and print solutions.
Japan 9466

Talk to a Data Expert

Have a question? We'll get back to you promptly.